Jana Mihályová, MD

physician
Department of Hematooncology, University Hospital, Czech Republic

Poster(s):

• 1508 - Measurable Residual Disease in Chronic Lymphocytic Leukemia (CLL) in Clinical Practice: A Single-Center Report Over the Years 2018–2024

• 1526 - Ibrutinib and acalabrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia: a real-world analysis from the Czech Chronic Lymphocytic Leukemia Patients Registry